1. Modlin IM, Lye KD, Kidd M. A 5‐decade analysis of 13,715 carcinoid tumors. Cancer. 2003 Feb 15;97(4):934-59.
2. Maggard MA, O'Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Annals of surgery. 2004 Jul 1;240(1):117-22.
3. Burkitt MD, Pritchard DM. Review article: pathogenesis and management of gastric carcinoid tumours. Alimentary pharmacology & therapeutics. 2006 Nov 1;24(9):1305-20.
4. Langseth H, Gislefoss RE, Martinsen JI. Cancer Registry of Norway, Cancer in Norway 2008. Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway. 2009.
5. Goh KL. Changing trends in gastrointestinal disease in the Asia–Pacific region. Journal of digestive diseases. 2007 Nov 1;8(4):179-85.
6. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. Journal of clinical epidemiology. 2003 Jan 31;56(1):1-9.
7. Solcia E, Rindi G, Buffa R, Fiocca R, Capella C. Gastric endocrine cells: types, function and growth. Regulatory peptides. 2000 Sep 25;93(1):31-5.
8. Burkitt MD, Pritchard DM: Review article: Pathogenesis and management of gastric carcinoid tumours. Aliment Pharmacol Ther 2006; 24:1305-20.
9. Borch K, Ahren B, Ahlman H, et al: Gastric carcinoids: Biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005; 242:64-73.
10. Borch K, Renvall H, Liedberg G: Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology 1985; 88:638-48.
11. Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surgical oncology. 2003 Aug 31;12(2):153-72.
12. Delle Fave G, Kwekkeboom DJ, Van Cutsem E, Rindi G, Kos-Kudla B, Knigge U, Sasano H, Tomassetti P, Salazar R, Ruszniewski P. ENETS consensus guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology. 2012;95(2):74-87.
13. Plöckinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, De Herder WW, Goede A, Caplin M, Öberg K, Reubi JC, Nilsson O. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. Neuroendocrinology. 2004;80(6):394-424.
14. Saund MS, Al Natour RH, Sharma AM, Huang Q, Boosalis VA, Gold JS. Tumor size and depth predict rate of lymph node metastasis and utilization of lymph node sampling in surgically managed gastric carcinoids. Annals of surgical oncology. 2011 Oct 1;18(10):2826-32.
15. Uygun A, Kadayifci A, Polat Z, Yilmaz K, Gunal A, Demir H, Bagci S. Long‐term results of endoscopic resection for type I gastric neuroendocrine tumors. Journal of surgical oncology. 2014 Feb 1;109(2):71-4.
16. Schindl M, Kaserer K, Niederle B. Treatment of gastric neuroendocrine tumors: the necessity of a type-adapted treatment. Archives of surgery. 2001 Jan 1;136(1):49-54.
17. Soga J. Early‐stage carcinoids of the gastrointestinal tract. Cancer. 2005 Apr 15;103(8):1587-95.
18. Gladdy RA, Strong VE, Coit D, Allen PJ, Gerdes H, Shia J, Klimstra DS, Brennan MF, Tang LH. Defining surgical indications for type I gastric carcinoid tumor. Annals of surgical oncology. 2009 Nov 1;16(11):3154-60.
19. Jordan PH, Barroso A, Sweeney J. Gastric carcinoids in patients with hypergastrinemia. Journal of the American College of Surgeons. 2004 Oct 31;199